KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Current Assets (2016 - 2025)

Historic Current Assets for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $786.9 million.

  • Emergent BioSolutions' Current Assets rose 1897.49% to $786.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $786.9 million, marking a year-over-year increase of 1897.49%. This contributed to the annual value of $598.7 million for FY2024, which is 1189.11% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Current Assets of $786.9 million as of Q3 2025, which was up 1897.49% from $719.5 million recorded in Q2 2025.
  • Emergent BioSolutions' Current Assets' 5-year high stood at $1.3 billion during Q4 2021, with a 5-year trough of $598.7 million in Q4 2024.
  • Moreover, its 5-year median value for Current Assets was $786.9 million (2025), whereas its average is $917.2 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 8849.35% in 2021, then plummeted by 4412.51% in 2024.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Current Assets stood at $1.3 billion in 2021, then dropped by 4.69% to $1.2 billion in 2022, then crashed by 43.86% to $679.5 million in 2023, then decreased by 11.89% to $598.7 million in 2024, then soared by 31.43% to $786.9 million in 2025.
  • Its last three reported values are $786.9 million in Q3 2025, $719.5 million for Q2 2025, and $706.8 million during Q1 2025.